AZRX AzurRx BioPharma Inc.

1.05
-0.03  -3%
Previous Close 1.08
Open 1.13
Price To Book 8.75
Market Cap 27,974,393
Shares 26,642,279
Volume 373,789
Short Ratio
Av. Daily Volume 588,283
Stock charts supplied by TradingView

NewsSee all news

  1. AzurRx BioPharma Announces Closing of $6.9 Million Private Placement

    NEW YORK, Jan. 13, 2020 (GLOBE NEWSWIRE) -- AzurRx BioPharma, Inc. (NASDAQ:AZRX) ("AzurRx" or the "Company"), a company specializing in the development of non-systemic, recombinant therapies for gastrointestinal

  2. AzurRx BioPharma To Present Interim Phase 2 Clinical Study Data for MS1819-SD, in combination with standard PERT for Cystic Fibrosis Patients with Severe Exocrine Pancreatic Insufficiency, at Biotech Showcase 2020 Conference (January 13) in San Francisco

    Initial data from the first five patients indicate positive trends for all primary and secondary safety and efficacy endpoints in AzurRx's Phase 2 Clinical Study for MS1819-SD, in combination with standard PERT for

  3. AzurRx BioPharma to Present at the Biotech Showcase 2020 Conference (January 13th)

    BROOKLYN, N.Y., Jan. 06, 2020 (GLOBE NEWSWIRE) -- AzurRx BioPharma, Inc. (NASDAQ:AZRX) ("AzurRx" or the "Company"), a company specializing in the development of non-systemic, recombinant therapies for gastrointestinal

  4. AzurRx BioPharma Announces Appointment of Daniel Schneiderman as Chief Financial Officer

    NEW YORK, Jan. 03, 2020 (GLOBE NEWSWIRE) -- AzurRx BioPharma, Inc. (NASDAQ:AZRX) ("AzurRx" or the "Company"), a company specializing in the development of non-systemic, recombinant therapies for gastrointestinal

  5. AzurRx BioPharma, Inc. Announces Equity Purchase Agreement for up to $15 Million with Lincoln Park Capital Fund, LLC

    NEW YORK, Nov. 14, 2019 (GLOBE NEWSWIRE) -- AzurRx BioPharma, Inc. (NASDAQ:AZRX) ("AzurRx" or the "Company"), a company specializing in the development of non-systemic, recombinant therapies for gastrointestinal

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Phase 2 higher dose trial to be initiated early 2020 with data due mid-2020.
MS1819-SD
Cystic fibrosis
Phase 2 data due 4Q 2020.
MS1819 Combination PERT-MS
Cystic Fibrosis Patients with Severe Exocrine Pancreatic Insufficiency

Latest News

  1. AzurRx BioPharma Announces Closing of $6.9 Million Private Placement

    NEW YORK, Jan. 13, 2020 (GLOBE NEWSWIRE) -- AzurRx BioPharma, Inc. (NASDAQ:AZRX) ("AzurRx" or the "Company"), a company specializing in the development of non-systemic, recombinant therapies for gastrointestinal

  2. AzurRx BioPharma To Present Interim Phase 2 Clinical Study Data for MS1819-SD, in combination with standard PERT for Cystic Fibrosis Patients with Severe Exocrine Pancreatic Insufficiency, at Biotech Showcase 2020 Conference (January 13) in San Francisco

    Initial data from the first five patients indicate positive trends for all primary and secondary safety and efficacy endpoints in AzurRx's Phase 2 Clinical Study for MS1819-SD, in combination with standard PERT for

  3. AzurRx BioPharma to Present at the Biotech Showcase 2020 Conference (January 13th)

    BROOKLYN, N.Y., Jan. 06, 2020 (GLOBE NEWSWIRE) -- AzurRx BioPharma, Inc. (NASDAQ:AZRX) ("AzurRx" or the "Company"), a company specializing in the development of non-systemic, recombinant therapies for gastrointestinal

  4. AzurRx BioPharma Announces Appointment of Daniel Schneiderman as Chief Financial Officer

    NEW YORK, Jan. 03, 2020 (GLOBE NEWSWIRE) -- AzurRx BioPharma, Inc. (NASDAQ:AZRX) ("AzurRx" or the "Company"), a company specializing in the development of non-systemic, recombinant therapies for gastrointestinal

  5. AzurRx BioPharma, Inc. Announces Equity Purchase Agreement for up to $15 Million with Lincoln Park Capital Fund, LLC

    NEW YORK, Nov. 14, 2019 (GLOBE NEWSWIRE) -- AzurRx BioPharma, Inc. (NASDAQ:AZRX) ("AzurRx" or the "Company"), a company specializing in the development of non-systemic, recombinant therapies for gastrointestinal

  6. AzurRx BioPharma Announces Positive CFF DSMB Review of Final Phase 2 OPTION Trial Data

    Supports Company plan to proceed to higher 4-gram dose of MS1819-SD in next Phase 2 clinical trialNo safety concerns cited for MS1819-SD NEW YORK, Oct. 17, 2019 (GLOBE NEWSWIRE) -- AzurRx BioPharma, Inc. (NASDAQ:AZRX)

  7. AzurRx BioPharma Announces First Patients Dosed in Clinical Study for MS1819-SD in combination with PERT for Cystic Fibrosis Patients with Severe Exocrine Pancreatic Insufficiency

    First cystic fibrosis (CF) patients with severe exocrine pancreatic insufficiency (EPI) treated in dose escalation study of MS1819-SD in combination with standard porcine pancreatic enzyme replacement therapy

  8. AzurRx BioPharma Announces Appointment of James Sapirstein as Chief Executive Officer

    NEW YORK, Oct. 10, 2019 (GLOBE NEWSWIRE) -- AzurRx BioPharma, Inc. (NASDAQ:AZRX) ("AzurRx" or the "Company"), a company specializing in the development of non-systemic, recombinant therapies for gastrointestinal

  9. AzurRx BioPharma Announces Positive Results from Phase 2 Trial with MS1819 in Cystic Fibrosis Patients

    Excellent safety results seen in CF patients, with CFA in line with previous studies and no need for a protease Management to discuss the results on a call scheduled for today, September 25, 2019 at 8:30 a.m. Eastern